Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Launched by BOEHRINGER INGELHEIM · Mar 26, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term use of Ofev Capsules in patients with a condition called systemic scleroderma associated interstitial lung disease (SSc-ILD) in Japan. The main goal is to see how often patients experience side effects, particularly gastrointestinal issues like diarrhea and nausea, when taking Ofev, using real-world experiences from patients rather than just data from clinical trials.

To be eligible for this study, patients must be living in Japan, have SSc-ILD, and be starting treatment with Ofev Capsules for the first time. The trial is currently active, but they are not recruiting new participants at this time. If you join, you can expect to share your experiences with the medication, helping researchers understand its effects in a real-life setting. This information is crucial for improving treatment options for others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients in Japan with SSc-ILD who are prescribed with Ofev Capsules and have never been treated with Ofev Capsules before enrolment will be included.
• Exclusion Criteria:
• • None.